Jonathan Rubenstein, MD
Ophthalmology · Chicago, ILNPI 1558413294
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Alcon at 52.1% of the total. 2025 is the largest year on record at $7,826, 2.0 times the $3,874 reported in 2019. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $344.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$19K
- Sight Sciences, Inc.$7K
- Alcon Research LLC$7K
- Rxsight Inc$2K
- Bausch & Lomb Americas Inc.$1K
- Oyster Point Pharma, Inc.$206
- plus $1K from 17 others
Across 6 payments — averaging $2299.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$14K
What the payments were for
- Consulting fees$19,85453%
- Speaking & faculty fees$12,75034%
- Travel & lodging$120%
- Food & beverage$4,52612%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 36 | $19,379 |
| Sight Sciences, Inc. | 10 | $6,775 |
| Alcon Research LLC | 12 | $6,646 |
| Rxsight Inc | 3 | $1,668 |
| Bausch & Lomb Americas Inc. | 5 | $1,435 |
| Oyster Point Pharma, Inc. | 5 | $206 |
| AbbVie(2 entities) | 9 | $189 |
| Aerie Pharmaceuticals, Inc. | 2 | $149 |
| Glaukos Corporation | 3 | $123 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $98 |
| Tarsus Pharmaceuticals, Inc. | 1 | $92 |
| Carl Zeiss Meditec USA, Inc. | 2 | $80 |
| Sun Pharmaceutical Industries Inc. | 3 | $65 |
| NEW World Medical,inc. | 3 | $40 |
| Novartis | 2 | $39 |
| Dompe US, Inc. | 1 | $32 |
| Spark Therapeutics, Inc. | 1 | $31 |
| Eyevance Pharmaceuticals LLC | 2 | $24 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $23 |
| Shire North American Group Inc | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Medtronic | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENUITY$13,153
- Luxor$10,003
- OMNI(R) SURGICAL SYSTEM (US)$6,617
- Clareon$5,932
- RXSIGHT CONTACT LENS$1,643
- RXSIGHT INJECTOR HANDPIECE$1,643
- RXSIGHT INJECTOR CARTRIDGE$1,643
- LIGHT ADJUSTABLE LENS (LAL)$1,643
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$1,643
- enVista MX60 IOL$1,374
- TENEO$1,250
- AcrySof$807
- Unity$135
- Rhopressa$127
- ENVISTA ENVY IOL$124
- STELLARIS$124
- Centurion$108
- OMNI$107
How this compares
$37,162 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 17 | $14,106 |
| Prednisolone Acetate | 217 | $8,424 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $7,842 |
| Loteprednol Etabonate | 35 | $4,797 |
| Cyclosporine | 16 | $4,090 |
| MoxifloxacinMoxifloxacin Hcl | 122 | $2,328 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $2,207 |
| Latanoprost | 159 | $2,073 |
| Fluorometholone | 12 | $2,042 |
| Difluprednate | 14 | $1,894 |
| Ketorolac Tromethamine | 77 | $1,187 |
| Timolol Maleate | 62 | $1,152 |
| ValacyclovirValacyclovir Hcl | 22 | $664 |
| Brimonidine Tartrate | 29 | $617 |
| Doxycycline Hyclate | 21 | $510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan | $189 | $21,94841 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $23 | $4,79735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Chicago
- Seenu HariprasadChicago$2.3M
- Yannek LeidermanChicago$312K
- Asim FarooqChicago$270K
- Dilraj GrewalChicago$188K
- Ahmad ArefChicago$179K
- Robert SchroederChicago$153K
- Jennifer LimChicago$150K
- Surendra BastiChicago$126K
- Allen PuttermanChicago$94K
- Maria CortinaChicago$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.